AEROPACE Device Gets Official FDA Patent Review Nod
Published Date: 2/26/2026
Notice
Summary
The FDA has set the official review period for the medical device AEROPACE, which helps the company extend its patent protection. This means the company could get more time to keep exclusive rights to their invention, potentially affecting competitors and consumers. If anyone thinks the dates are wrong or the company wasn’t careful during the review, they can speak up by April 27 or August 25, 2026.
Analyzed Economic Effects
4 provisions identified: 1 benefits, 2 costs, 1 mixed.
FDA Sets 2,802-Day Review Period
The FDA determined the regulatory review period for the medical device AEROPACE is 2,802 days in total: 2,561 days in the testing phase and 241 days in the approval phase. That review-period length is the basis the company can use when applying for up to a 5-year patent extension and may give the company more time to keep exclusive rights, which could affect competitors and consumers.
Applicant Seeks 1,288 Days Extension
Lungpacer Medical, Inc. has applied to the USPTO seeking 1,288 days of patent term extension for U.S. Patent No. 10,765,867 for AEROPACE. The FDA notes its determination establishes the maximum potential length, but the USPTO will apply statutory limitations when calculating the actual extension.
Public Comment and Petition Deadlines
Anyone who believes the published dates are incorrect may ask for a redetermination by April 27, 2026. Any interested person may petition the FDA to challenge whether the applicant acted with due diligence by August 25, 2026, following the petition procedures in 21 CFR 60.30.
FDA Rejects Applicant's Earlier Date Claims
The applicant claimed an IDE effective date of March 2, 2017 and a PMA initial submission date of February 11, 2022, but FDA records show the IDE was effective April 5, 2017 and PMA P240012 was submitted on April 8, 2024. FDA used its dates when determining the regulatory review period.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-03848 — Determination of Regulatory Review Period for Purposes of Patent Extension; ORLYNVAH
The FDA has set the official review period for ORLYNVAH, a human drug, which helps decide how long its patent can be extended. This affects the drug’s maker by potentially giving them more time to protect their invention and earn money. If anyone thinks the dates are wrong or wants to challenge the company’s effort during review, they have until April 27 or August 25, 2026, to speak up.
Next: 2026-03850 — Determination of Regulatory Review Period for Purposes of Patent Extension; TRYNGOLZA
The FDA has officially set the review period for the drug TRYNGOLZA, which helps the company extend its patent protection. This means the drug maker could get extra time to keep their invention exclusive, potentially affecting competition and market prices. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by April 27 or August 25, 2026.